John Tsai's most recent trade in Blueprint Medicines Corp was a trade of 4,570 Stock Option (Right to Buy) done . Disclosure was reported to the exchange on June 12, 2024.
Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
---|---|---|---|---|---|---|---|---|---|---|
Blueprint Medicines Corp | John Tsai | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Jun 2024 | 4,570 | 4,570 | - | - | Stock Option (Right to Buy) | |
Blueprint Medicines Corp | John Tsai | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Jun 2024 | 2,242 | 8,742 (0%) | 0% | 0 | Common Stock | |
Blueprint Medicines Corp | John Tsai | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Jun 2023 | 5,300 | 5,300 | - | - | Stock Option (Right to Buy) | |
Blueprint Medicines Corp | John Tsai | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Jun 2023 | 2,600 | 6,500 (0%) | 0% | 0 | Common Stock | |
Blueprint Medicines Corp | John Tsai | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Jan 2023 | 7,950 | 7,950 | - | - | Stock Option (Right to Buy) | |
Blueprint Medicines Corp | John Tsai | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Jan 2023 | 3,900 | 3,900 (0%) | 0% | 0 | Common Stock |